Analysis of Reportable Segments
CVS Health Corp. operates in 4 segments: Health Care Benefits; Health Services; Pharmacy & Consumer Wellness; and Corporate/Other.
Segment Profit Margin
CVS Health Corp., profit margin by reportable segment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Health Care Benefits | 0.24% | 5.32% | 6.97% | 6.27% | — |
| Health Services | 4.18% | 3.91% | 4.00% | 4.22% | — |
| Pharmacy & Consumer Wellness | 4.64% | 5.11% | 6.01% | 7.15% | — |
| Corporate/Other | -2,407.14% | -2,312.28% | -1,300.81% | -1,308.00% | — |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
An analysis of segment profit margins from 2021 through 2024 reveals divergent performance trends across the primary business units, characterized by significant margin compression in health benefits and a steady decline in pharmacy operations, contrasted by relative stability in health services.
- Health Care Benefits
- This segment experienced significant volatility and a severe downward trajectory. After reaching a peak margin of 6.97% in 2022, the profit margin declined to 5.32% in 2023 and collapsed to 0.24% by December 31, 2024, indicating a near-total erosion of profitability within this segment.
- Health Services
- Profitability within Health Services remained the most stable of all reportable segments. Margins fluctuated minimally, moving from 4.22% in 2021 to a low of 3.91% in 2023, before recovering slightly to 4.18% in 2024.
- Pharmacy & Consumer Wellness
- A consistent and linear contraction in profit margins is observed in this segment. Starting at 7.15% in 2021, the margin decreased every consecutive year, falling to 6.01% in 2022, 5.11% in 2023, and finishing at 4.64% in 2024.
- Corporate/Other
- The Corporate/Other category reflects substantial and widening negative margins. The deficit deepened significantly after 2021, moving from -1,308.00% to -2,407.14% by the end of 2024, representing a marked increase in non-segment corporate costs relative to revenue.
Overall, the aggregate trend indicates a tightening of profitability across most segments, with the Health Care Benefits and Pharmacy & Consumer Wellness units showing the most pronounced declines in operational efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Health Care Benefits
CVS Health Corp.; Health Care Benefits; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Adjusted operating income (loss) | 307) | 5,577) | 6,338) | 5,110) | —) |
| Revenues | 129,192) | 104,881) | 90,874) | 81,533) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 0.24% | 5.32% | 6.97% | 6.27% | — |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Adjusted operating income (loss) ÷ Revenues
= 100 × 307 ÷ 129,192 = 0.24%
The Health Care Benefits segment exhibits a significant divergence between revenue growth and operating profitability from 2021 through 2024. While top-line performance demonstrated consistent and accelerating growth, operating income and profit margins experienced a severe contraction after 2022.
- Revenue Growth Trends
- A continuous upward trajectory in revenues is observed, increasing from 81,533 million US dollars in 2021 to 129,192 million US dollars in 2024. The growth rate accelerated toward the end of the period, with the most substantial absolute increase occurring between 2023 and 2024.
- Operating Income Performance
- Adjusted operating income peaked in 2022 at 6,338 million US dollars. However, a sharp reversal occurred thereafter, with income falling to 5,577 million US dollars in 2023 and plummeting to 307 million US dollars by 2024. This indicates that the increase in revenue was insufficient to offset rising operational costs or losses during the final two years of the period.
- Segment Profit Margin Analysis
- The segment profit margin peaked at 6.97% in 2022, reflecting the period of highest operational efficiency. A subsequent decline followed, with the margin dropping to 5.32% in 2023 and collapsing to 0.24% in 2024. The precipitous drop in margin despite record-high revenues suggests a significant increase in the cost of providing benefits or other systemic operational pressures.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Health Services
CVS Health Corp.; Health Services; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Adjusted operating income (loss) | 7,243) | 7,312) | 6,781) | 6,492) | —) |
| Revenues | 173,320) | 186,844) | 169,576) | 153,892) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 4.18% | 3.91% | 4.00% | 4.22% | — |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Adjusted operating income (loss) ÷ Revenues
= 100 × 7,243 ÷ 173,320 = 4.18%
The Health Services segment exhibited a period of revenue expansion followed by a contraction, while adjusted operating income remained relatively stable across the analyzed timeframe.
- Revenue Trends
- Revenues demonstrated consistent growth from 2021 through 2023, rising from US$ 153,892 million to a peak of US$ 186,844 million. This upward trajectory reversed in 2024, with revenues decreasing to US$ 173,320 million.
- Adjusted Operating Income Performance
- Adjusted operating income increased steadily between 2021 and 2023, moving from US$ 6,492 million to US$ 7,312 million. In 2024, the figure remained largely resilient, experiencing only a marginal decline to US$ 7,243 million despite the reduction in total revenues.
- Segment Profit Margin Analysis
- The segment profit margin underwent a period of compression from 2021 to 2023, declining from 4.22% to 3.91%. A reversal of this trend is observed in 2024, with the margin recovering to 4.18%. The expansion of the profit margin in 2024, occurring simultaneously with a decline in revenue, indicates an improvement in operational efficiency or a successful reduction in the cost of services provided.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Pharmacy & Consumer Wellness
CVS Health Corp.; Pharmacy & Consumer Wellness; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Adjusted operating income (loss) | 5,774) | 5,963) | 6,531) | 7,260) | —) |
| Revenues | 124,500) | 116,768) | 108,640) | 101,603) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 4.64% | 5.11% | 6.01% | 7.15% | — |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Adjusted operating income (loss) ÷ Revenues
= 100 × 5,774 ÷ 124,500 = 4.64%
The Pharmacy & Consumer Wellness segment exhibits a divergent trend between top-line growth and operational profitability from 2021 through 2024. While revenues have increased consistently, adjusted operating income has declined over the same period, resulting in a sustained compression of the segment profit margin.
- Revenue Trajectory
- Revenues demonstrated steady annual growth, rising from 101,603 million USD in 2021 to 124,500 million USD in 2024. This indicates a consistent expansion in the segment's scale of operations and market reach.
- Operating Income Performance
- Adjusted operating income followed an inverse trajectory to revenue, decreasing every year from a peak of 7,260 million USD in 2021 to 5,774 million USD in 2024. This decline suggests that operating expenses have outpaced revenue gains, eroding the absolute profitability of the segment.
- Profit Margin Analysis
- The segment profit margin contracted steadily from 7.15% in 2021 to 4.64% in 2024. This downward trend confirms a significant reduction in operational efficiency, as the segment generated progressively less profit for every dollar of revenue earned over the four-year period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Corporate/Other
CVS Health Corp.; Corporate/Other; segment profit margin calculation
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Adjusted operating income (loss) | (1,348) | (1,318) | (1,613) | (1,635) | —) |
| Revenues | 56) | 57) | 124) | 125) | —) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | -2,407.14% | -2,312.28% | -1,300.81% | -1,308.00% | — |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Segment profit margin = 100 × Adjusted operating income (loss) ÷ Revenues
= 100 × -1,348 ÷ 56 = -2,407.14%
The Corporate/Other segment exhibits a consistent pattern of significant operating losses paired with a diminishing revenue base, resulting in a severe deterioration of the segment profit margin between 2021 and 2024.
- Adjusted Operating Income Trends
- The segment has maintained a substantial operating loss throughout the analyzed period. After a peak loss of 1,635 million US dollars in 2021, the deficit narrowed slightly to 1,318 million US dollars by 2023, before increasing again to 1,348 million US dollars in 2024. This indicates a relatively stable level of corporate overhead and expenses that do not fluctuate in direct proportion to the segment's nominal revenue.
- Revenue Performance
- A sharp contraction in revenue is observed. Revenues remained stable at approximately 124 to 125 million US dollars during 2021 and 2022, but experienced a significant decline starting in 2023, falling to 57 million US dollars. This downward trend continued into 2024, with revenue settling at 56 million US dollars, representing a reduction of more than 50% from 2021 levels.
- Segment Profit Margin Analysis
- The segment profit margin has declined precipitously, moving from -1,308.00% in 2021 to -2,407.14% in 2024. The extreme negative trajectory of the margin is primarily driven by the combination of persistent high operating losses and a shrinking revenue denominator. While operating losses improved slightly between 2021 and 2023, the simultaneous halving of revenue caused the margin to expand negatively from -1,300.81% in 2022 to -2,312.28% in 2023, further worsening in 2024.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Revenues
CVS Health Corp., revenues by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Health Care Benefits | 129,192) | 104,881) | 90,874) | 81,533) | —) |
| Health Services | 173,320) | 186,844) | 169,576) | 153,892) | —) |
| Pharmacy & Consumer Wellness | 124,500) | 116,768) | 108,640) | 101,603) | —) |
| Corporate/Other | 56) | 57) | 124) | 125) | —) |
| Intersegment eliminations | (56,412) | (51,927) | (47,585) | (46,241) | —) |
| Consolidated total | 370,656) | 356,623) | 321,629) | 290,912) | —) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Consolidated revenues demonstrate a consistent upward trajectory over the four-year period, increasing from $290.9 billion in 2021 to $370.7 billion by the end of 2024. This overall growth is driven by varying performance levels across the reportable segments, with a notable shift in the primary drivers of revenue expansion.
- Health Care Benefits
- This segment exhibited the most aggressive growth of all reportable units. Revenues rose steadily from $81.5 billion in 2021 to $129.2 billion in 2024. The acceleration is particularly evident between 2022 and 2024, where the segment saw a substantial increase, indicating a significant expansion in the scale of health benefits operations.
- Health Services
- Revenues in this segment showed an initial growth phase, peaking at $186.8 billion in 2022. However, a reversal occurred in 2024, with revenues declining to $173.3 billion. This represents the only major segment to experience a contraction in the final year of the period analyzed, offsetting some of the gains made in other areas.
- Pharmacy and Consumer Wellness
- A pattern of steady, linear growth is observed in this segment. Revenues increased incrementally from $101.6 billion in 2021 to $124.5 billion in 2024. This suggests a stable and predictable expansion of the pharmacy and retail wellness business.
- Intersegment Eliminations and Corporate Items
- Intersegment eliminations increased in absolute value from -$46.2 billion in 2021 to -$56.4 billion in 2024. The rise in eliminations suggests an increase in the volume of internal transactions and integrated service delivery between the different business segments. Meanwhile, corporate and other revenues declined marginally, remaining a negligible component of the total revenue structure.
The analysis indicates a strategic shift in the revenue mix. While Health Services was the largest contributor for much of the period, the rapid expansion of Health Care Benefits has significantly altered the composition of the consolidated total, contributing to the continued growth of the organization despite the recent contraction in Health Services.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Adjusted operating income (loss)
CVS Health Corp., adjusted operating income (loss) by reportable segment
US$ in millions
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Health Care Benefits | 307) | 5,577) | 6,338) | 5,110) | —) |
| Health Services | 7,243) | 7,312) | 6,781) | 6,492) | —) |
| Pharmacy & Consumer Wellness | 5,774) | 5,963) | 6,531) | 7,260) | —) |
| Corporate/Other | (1,348) | (1,318) | (1,613) | (1,635) | —) |
| Consolidated total | 11,976) | 17,534) | 18,037) | 17,227) | —) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Consolidated adjusted operating income exhibited a period of relative stability and modest growth between 2021 and 2023, followed by a substantial contraction in 2024. Total operating income peaked in 2022 at 18,037 million USD before declining to 11,976 million USD by the end of 2024, representing a significant reduction in overall profitability.
- Health Care Benefits
- This segment demonstrated the highest level of volatility. After an initial increase from 5,110 million USD in 2021 to a peak of 6,338 million USD in 2022, a severe downward trend emerged. The operating income collapsed to 307 million USD by 2024, indicating a critical erosion of profitability within this specific business line.
- Health Services
- The Health Services segment remained the most stable contributor to operating income. It showed a consistent upward trajectory from 6,492 million USD in 2021 to a peak of 7,312 million USD in 2023, ending 2024 with a marginal decrease to 7,243 million USD. This segment currently serves as the primary driver of consolidated operating results.
- Pharmacy & Consumer Wellness
- A persistent and linear decline is observed in this segment. Operating income decreased every year from 7,260 million USD in 2021 to 5,774 million USD in 2024. This steady contraction suggests systemic pressure on margins or a reduction in operational efficiency within the pharmacy and retail operations.
- Corporate/Other
- Corporate and other expenses remained relatively consistent as a negative impact on consolidated results. The losses narrowed slightly from 1,635 million USD in 2021 to 1,348 million USD in 2024, indicating that corporate overhead has remained stable relative to the volatility seen in the primary operating segments.
The overall financial trajectory indicates a shift in the company's profit composition. While Health Services has maintained its performance, the combined deterioration of the Pharmacy & Consumer Wellness segment and the precipitous drop in Health Care Benefits have led to a significant decline in the consolidated adjusted operating income by 2024.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?